Synthetic Biologics Культура компании

Dr. Raymond D. Stapleton, Jr., also Known as Ray, PhD has been Senior Vice President of Manufacturing at Synthetic Biologics Inc. since October 2015. Dr. Stapleton leads the manufacturing team as Synthetic Biologics begins to prepare for late-stage clinical trials for its irritable bowel syndrome with constipation (IBS-C) and C. difficile programs and continues to move its monoclonal antibody (mAb) program forward to address Pertussis (whooping cough). Dr. Stapleton is a pharmaceutical and biotechnology executive with more than 15 years of experience at Merck & Co., Inc., in manufacturing, operations, quality, science, technology, engineering and process development. He served as Executive Director of Global Vaccine Technology and Engineering. During his tenure at Merck, he contributed to the scale up, tech transfer and manufacturing product launch of multiple billion dollar franchises including ISENTRESS?? (oral solid dosage for AIDs), GARDASIL?? (HPV vaccine), KEYTRUDA?? (anti-PD-1 cancer mAb therapy), and performed process development for the cholesterol lowering therapy MEVACOR?? (lovastatin). Dr. Stapleton has served for 10 years as a member of the Journal of Industrial Microbiology and Biotechnology review board and is an ad hoc reviewer for several journals including Environmental Science and Technology, Antonie von Leeuwenhook and Enzyme and Microbial Technology. He has co-edited a book and co-authored patents, as well as several peer-reviewed manuscripts and presentations. He was the recipient of an Alexander Hollaender Fellowship for post-doctoral studies in the Environmental Science Division at Oak Ridge National Laboratory. Dr. Stapleton earned a PhD in microbial ecology from The Center for Environmental Biotechnology at The University of Tennessee, Knoxville and a BS degree in biology from Mary Washington College.

Dr. Joseph A. Sliman, also known as Joe, M.D., M.P.H. has been Chief Medical Officer at Synthetic Biologics, Inc. since January 17, 2017. Dr. Sliman has more than 18 years of experience in clinical and public health research, including 10 years directing clinical projects and product development, in therapeutic areas such as infectious diseases and vaccines. He Senior Vice President of Clinical and Regulatory Affairs at Synthetic Biologics, Inc. from January 13, 2014 to January 17, 2017. Dr. Sliman served as a Senior Medical Director and Head of Patient Safety and Pharmacovigilance at Vanda Pharmaceuticals Inc., where he directed efforts for a New Drug Application for HETLIOZ (tasimelteon), which is indicated for the treatment of Non-24 Hour Disorder in totally blind adults. Prior to this time, he served as Medical Director in Vaccines and Infectious Diseases at MedImmune, Inc., where he was a member of successful Biologics Licensure Application teams. Prior to joining MedImmune, he served as Associate Medical Director at Dynport Vaccine Company, where he was the clinical director for seasonal and pandemic influenza vaccine trials as well as its Defense Vaccines development program (partnered with Department of Defense Joint Vaccines Acquisition Program). During his service in the United States Navy, Dr. Sliman led the U. S. Pacific Fleet disease surveillance programs, including influenza surveillance, preparedness and prevention, as well as communicable disease and injury surveillance and prevention and health policy development. Dr. Sliman earned an M.D. from the Uniformed Services University, a Master's Degree in Public Health from the Johns Hopkins University School of Public Health and a B.S. in Molecular and Cell Biology, with Honors in Biology, from Pennsylvania State University.

Mr. Scott L. Tarriff founded Eagle Pharmaceuticals Inc. in January 2007 and has been its Chief Executive Officer since January 2007. Mr. Tarriff served as the Chief Executive Officer and President at Par Pharmaceutical Companies Inc. from September 16, 2003 to September 2006. He served as the President of Eagle Pharmaceuticals Inc., from January 2007 to January 02, 2017. He also served as an Executive Vice President of Par Pharmaceutical Companies Inc. since January 1998. He served as Executive Vice President of Business, Chief Executive Officer and President of Par Pharmaceutical Inc., a subsidiary of Par Pharmaceutical Companies, Inc. since September 2001. He joined Par Pharmaceutical Companies in 1998. From 1995 to 1997, Mr. Tarriff served as Senior Director of Marketing Business Development and Strategic Planning of the Apothecon division at Bristol-Myers Squibb. He has more than 25 years of pharmaceutical experience. He served as the Chairman and Director of Kali Laboratories, Inc., a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. Mr. Tarriff serves as a Director of Hillcrest Health Service System, Inc. He has been a Director of ZIOPHARM Oncology, Inc. since September 28, 2015. He has been an Director of Eagle Pharmaceuticals Inc., since January 2007. He has been an Independent Director at Synthetic Biologics, Inc. (Formerly, Adeona Pharmaceuticals, Inc.) since February 3, 2012. Mr. Tarriff served as Director of Par Pharmaceutical Companies Inc. from 2002 to September 2006. He served as a Director of Clinical Data, Inc. from September 2009 to April 13, 2011. He has been recognized as a visionary leader in the pharmaceutical industry where his marketing and business development expertise has been utilized to set new standards and to provide greater value for customers and stakeholders. He serves as Member of Board of Governors and Member of Advisory Board of Hackensack University Medical Center. Mr. Tarriff holds and a B.S. in Marketing from Pennsylvania State University and an MBA from Rider College.

Deb Mathews serves as the Vice President, Medical Affairs of Synthetic Biologics, Inc.. Deb started at Synthetic Biologics, Inc. in May of 2016. Deb is currently based in the Greater Philadelphia Area.

John Kokai-Kun serves as the Vice President of Project Management and Non-clinical Affairs of Synthetic Biologics, Inc.. John started at Synthetic Biologics, Inc. in December of 2017. John is currently based in the Washington D.C. Metro Area.

Joe Sliman serves as the Chief Medical Officer of Synthetic Biologics, Inc.. Joe started at Synthetic Biologics, Inc. in January of 2017. Joe is currently based in the Washington D.C. Metro Area.

Raymond Stapleton serves as the Senior Vice President - Manufacturing of Synthetic Biologics, Inc.. Raymond started at Synthetic Biologics, Inc. in October of 2015. Raymond is currently based in the Washington D.C. Metro Area.

Andrew Bristol serves as the Vice President, Development of Synthetic Biologics, Inc.. Andrew started at Synthetic Biologics, Inc. in October of 2012. Andrew is currently based in the Washington D.C. Metro Area.